1 / 10

The Need for 3rd-Line Therapy in Non-Small Cell Lung Cancer

rae
Download Presentation

The Need for 3rd-Line Therapy in Non-Small Cell Lung Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. The Need for 3rd-Line Therapy in Non-Small Cell Lung Cancer Frances A. Shepherd, MD Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital Professor of Medicine, University of Toronto

    2. CRC-2 Most Patients With NSCLC Will Require Systemic Therapy

    3. CRC-3 Systemic Treatment for Advanced NSCLC Chemotherapy 1st-Line Modestly improves survival and symptoms Platinum-based regimens the standard Uncertain benefit in patients with PS 2 Toxicity an issue 1st- and 2nd-line

    4. CRC-4 2nd-Line Treatment for NSCLC Docetaxel is the only chemotherapy approved for NSCLC Response rate is low only 6% to 7% Demonstrated benefit in terms of survival and symptom control Toxicity is an issue

    5. CRC-5 3rd-Line Treatment for Advanced NSCLC For NSCLC, no standard definition for disease refractory to both platinum and docetaxel Clinical definition of 3rd-line: patients previously treated with a platinum and docetaxel who are not expected to benefit from additional treatment with same Single-agent chemotherapy now used for 3rd-line

    6. CRC-6 Outcomes in NSCLC Patients From Start of 3rd- and 4th-Line Therapy

    7. CRC-7 NSCLC Commonly Causes Disease-Related Symptoms Specific symptoms Shortness of breath Cough Tightness in the chest Difficulty breathing Poor Appetite and Weight loss Fatigue Type, severity, frequency depend on tumor location, disease burden, and growth rate

    8. CRC-8 Significance of Objective Responses in 3rd-Line Therapy of NSCLC Measure of antitumor activity Associated with symptom improvement Associated with better patient outcomes

    9. CRC-9 Disease-Related Symptoms in NSCLC When asked, 68% of patients with NSCLC who had already received platinum, stated they would choose chemotherapy compared to best supportive care if symptoms could be substantially reduced, even if survival was not prolonged

    10. CRC-10 Goals of 3rd-Line Therapy in NSCLC Improve disease-related symptoms Improve performance status Treatment not an additional burden Enhanced patient control Holiday from IV therapy Less time away from home for treatment

    11. CRC-11 3rd-Line Therapy for Non-Small Cell Lung Cancer: an Unmet Need Increasing numbers of patients with NSCLC for 3rd-line therapy Most of these patients have significant disease-related symptoms No approved 3rd-line agents Standard chemotherapies a poor solution 3rd-line therapy for NSCLC represents an unmet medical need

More Related